Nine insiders at Scribe Therapeutics, Inc. (SCTX) collectively purchased approximately $75 million worth of company stock on July 29, 2026. Among the notable buyers were Advisors Llc Orbimed, Carl L. Gordon, and Capital Gp Viii Llc Orbimed, each acquiring 1,000,000 shares at $15.00 per share, totaling $15 million for each entity.
Additional significant purchases were made by 10% owners Equity Partners Bio Ii, L.L.C. Ah, Bio Fund Iii, L.P. Ah, Equity Partners Bio Iii, L.L.C. Ah, Benjamin A. Horowitz, and Marc L. Andreessen, along with Bio Fund Ii, L.P. Ah, each acquiring 333,333 shares at the same price point, amounting to approximately $5 million each.
This coordinated buying activity among multiple insiders is often interpreted as a strong bullish signal by market observers, suggesting confidence in the company's future prospects. The purchases occurred amidst recent insider activity from other entities, including Avoro Capital Advisors LLC and Aghazadeh Behzad, who also made smaller buy transactions the previous day.